CASP3 polymorphisms and risk of squamous cell carcinoma of the head and neck

Clinical Cancer Research

Volumn 14, Issue 19, 2008, Pages 6343-6349

  Chen, Kexin ^a   Zhao, Hui ^c   Hu, Zhibin ^b   Wang, Li E ^c   Zhang, Wei ^c   Sturgis, Erich M ^c   Wei, Qingyi ^c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; OROPHARYNX CANCER; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA; 5' UNTRANSLATED REGION; CASE CONTROL STUDY; GENETIC POLYMORPHISM; GENETICS; HEAD AND NECK TUMOR; MIDDLE AGED; REGRESSION ANALYSIS; RISK;

5' UNTRANSLATED REGIONS; AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CASPASE 3; FEMALE; HAPLOTYPES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; RISK;

EID: 58149154714     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1198     Document Type: Article

References (34)

1. Ragin CC, Modugno F, Gollin SM. The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res 2007;86:104-14.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
3. Paz-Elizur T, Ben-Yosef R, Elinger D, et al. Reduced repair of the oxidative 8-oxoguanine DNA damage and risk of head and neck cancer. Cancer Res 2006;66:11683-9.
4. Yang M, Kim WH, Choi Y, et al. Effects of ERCC1 expression in peripheral blood on the risk of head and neck cancer. Eur J Cancer Prev 2006;15:269-73.
5. Ho T, Wei Q, Sturgis EM. Epidemiology of carcinogen metabolism genes and risk of squamous cell carcinoma of the head and neck. Head Neck 2007;29:682-99.
6. Gattas GJ, de Carvalho MB, Siraque MS, et al. Genetic polymorphisms of CYP1A1, CYP2E1, GSTM1, and GSTT1 associated with head and neck cancer. Head Neck 2006;28:819-26.
7. Li G, Liu Z, Sturgis EM, et al. Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck. Carcinogenesis 2005;26:1596-602.
8. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770-6.
9. Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends Biochem Sci 1997;22:299-306.
10. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999;15:269-90.
11. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003;22:8543-67.
12. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999;11:255-60.
13. Bodmer JL, Holler N, Reynard S, et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000;2:241-3.
14. Nagata S. Apoptosis by death factor. Cell 1997;88:355-65.
15. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-89.
16. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1998;1:949-57.
17. Juo P, Kuo CJ, Yuan J, Blenis J. Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr Biol 1998;8:1001-8.
18. Kischkel FC, Lawrence DA, Tinel A, et al. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 2001;276:46639-46.
19. Adrain C, Martin SJ. The mitochondrial apoptosome: a killer unleashed by the cytochrome seas. Trends Biochem Sci 2001;26:390-7.
20. Soung YH, Lee JW, Kim SY, et al. Somatic mutations of CASP3 gene in human cancers. Hum Genet 2004;115:112-5.
21. Kurokawa H, Nishio K, Fukumoto H, Tomonari A, Suzuki T, Saijo N. Alteration of caspase-3 (CPP32/Yama/apopain) in wild-type MCF-7, breast cancer cells. Oncol Rep 1999;6:33-7.
22. Fujikawa K, Shiraki K, Sugimoto K, et al. Reduced expression of ICE/caspase1 and CPP32/caspase3 in human hepatocellular carcinoma. Anticancer Res 2000;20:1927-32.
23. Kania J, Konturek SJ, Marlicz K, Hahn EG, Konturek PC. Expression of survivin and caspase-3 in gastric cancer. Dig Dis Sci 2003;48:266-71.
24. Tormanen-Napankangas U, Soini Y, Kahlos K, Kinnula V, Paakko P. Expression of caspases-3, -6 and -8 and their relation to apoptosis in non-small cell lung carcinoma. Int J Cancer 2001;93:192-8.
25. Lan Q, Zheng T, Chanock S, et al. Genetic variants in caspase genes ands usceptibility to non-Hodgkin lymphoma. Carcinogenesis 2007;28:823-7.
26. Sun T, Gao Y, Tan W, et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet 2007;39:605-13.
27. Son JW, Kang HK, Chae MH, et al. Polymorphisms in the caspase-8 gene and the risk of lung cancer. Cancer Genet Cytogenet 2006;169:121-7.
28. Park JY, Park JM, Jang JS, et al. Caspase 9 promoter polymorphisms and risk of primary lung cancer. Hum Mol Genet 2006;15:1963-71.
29. Shen H, Sturgis EM, Khan SG, et al. An intronic poly (AT) polymorphism of the DNA repair gene XPC and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Res 2001;61:3321-5.
30. American Joint Committee on Cancer. Manual for staging of cancer. 6th ed. Philadelphia: JB Lippincott; 2002.
31. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003;73:1162-9.
32. Mandruzzato S, Brasseur F, Andry G, Boon T, van der Bruggen P. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med 1997;186:785-93.
33. Wang J, Zheng L, Lobito A, et al. Inherited human caspase 10 mutations underlie defective lymphocyte andd endritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 1999;98:47-58.
34. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602.